CalciMedica Acquires Exclusive Rights to Novel Immune Signaling Targets for Treating Autoimmune Diseases from The CBR Institute May 7, 2007
TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica May 7, 2007